Research-to-Action

Expanded highly active antiretroviral therapy (HAART) coverage is associated with a 50 percent decrease in new yearly HIV infections among injection drug users, a new study has found

Asian News International
Friday, February 19, 2010

A comprehensive population-based study, conducted by the BC Centre for Excellence in HIV/AIDS (BC-CfE) and presented at the 17th Conference on Retroviruses and Opportunistic Infections in San Francisco, shows that expanded highly active antiretrovial therapy (HAART) coverage was associated with a 50% decrease in new yearly HIV infections among injection drug users.

These results were temporally related to an outreach effort specifically targeting injection drug users. In addition, increased HAART coverage was assocated with a decrease in the community HIV plasma viral load in British Columbia.